In murine models, blocking the PD-1 pathway via genetic knockdown or through the administration of blocking antibodies increases the risk for developing autoimmune dilated cardiomyopathy and experimental autoimmune encephalomyelitis [26]. The gene discussed is PDCD1; the disease is experimental autoimmune encephalomyelitis.